top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hIL1B mice
Strain Name C57BL/6-Il1btm1(ILIB)/Bcgen Common Name  B-hIL1B mice
Background C57BL/6 Catalog number  110075
Related Genes 
interleukin 1 beta, IL-1; IL1F2; IL1beta; IL1-BETA
NCBI Gene ID
16176

mRNA expression analysis


from clipboard



Strain specific analysis of IL1B gene expression in B-hIL1B mice by RT-PCR. Mouse Il1b was detectable in splenocytes of wild-type mice (+/+). Human IL1B was detectable only in homozygous B-hIL1B mice (H/H) but not in wild-type mice.


Protein expression analysis

from clipboard


Strain specific IL1B expression analysis in homozygous B-hIL1B mice by ELISA. 
Bone marrow cell supernatant were collected from C57BL/6(+/+) and  homozygous B-hIL1B mice(H/H) stimulated with LPS in vivo, and analyzed by ELISA with species-specific IL1B ELISA kit. Mouse IL1B was detectable in C57BL/6 mice. Human IL1B was exclusively detectable in homozygous B-hIL1B  mice but not C57BL/6 mice. ND, not detectable. 


Analysis of spleen leukocytes cell subpopulations in B-hIL1B mice 


from clipboard



Analysis of spleen leukocyte subpopulations by FACS. 
Splenocytes were isolated from female C57BL/6 and B-hIL1B mice (n=5, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hIL1B mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL1B in place of its mouse counterpart dose not change the overall development, differentiation or distribution of these cell types in spleen. Values are expressed as mean ± SEM.


Analysis of spleen T cell subpopulations in B-hIL1B mice

from clipboard



Analysis of spleen T cell subpopulations by FACS.
Splenocytes were isolated from female C57BL/6 and B-hIL1B mice (n=5, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for TCRβ+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8+ T cells, CD4+ T cells, and Treg cells in homozygous B-hIL1B mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL1B in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in spleen. Values are expressed as mean ± SEM.


Analysis of Lymph node leukocytes cell subpopulations in B-hIL1B mice


from clipboard


Analysis of lymph node leukocyte subpopulations by FACS
Lymphocytes were isolated from female C57BL/6 and B-hIL1B mice (n=5, 6-week-old). Flow cytometry analysis of the Lymphocyte was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hIL1B mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL1B in place of its mouse counterpart dose not change the overall development, differentiation or distribution of these cell types in lymph node. Values are expressed as mean ± SEM.


Analysis of Lymph node T cell subpopulations in B-hIL1B mice

from clipboard


Analysis of lymph node T cell subpopulations by FACS
Lymphocytes were isolated from female C57BL/6 and B-hIL1B mice (n=5, 6-week-old). Flow cytometry analysis of the Lymphocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for TCRβ+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8+ T cells, CD4+ T cells, and Treg cells in homozygous B-hIL1B mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL1B in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in lymph node. Values are expressed as mean ± SEM.


Analysis of blood leukocytes cell subpopulations in B-hIL1B mice 

from clipboard


Analysis of blood leukocyte subpopulations by FACS. 
Blood cells were isolated from female C57BL/6 and B-hIL1B mice (n=5, 6-week-old). Flow cytometry analysis of the blood cells was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hIL1B mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL1B in place of its mouse counterpart dose not change the overall development, differentiation or distribution of these cell types in blood. Values are expressed as mean ± SEM.


Analysis of blood T cell subpopulations in B-hIL1B mice



from clipboard


Analysis of blood T cell subpopulations by FACS
Blood cells were isolated from female C57BL/6 and B-hIL1B mice (n=5, 6-week-old). Flow cytometry analysis of the blood cells was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live CD45+ cells were gated for TCRβ+ T cell population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of CD8+ T cells, CD4+ T cells, and Treg cells in homozygous B-hIL1B mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL1B in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in blood. Values are expressed as mean ± SEM.


In vivo efficacy of anti human IL1B antibody


from clipboard


Antitumor activity of anti-human IL1B antibody in B-hIL1B mice. (A) Anti-human IL1B antibody canakinumab (in house) inhibited MC38 tumor growth in B-hIL1B mice. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hIL1B mice (female, 6 week-old, n=5). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with anti-human IL1B antibody canakinumab(in house) with different doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, anti-human IL1B antibody canakinumab(in house) was efficacious in controlling tumor growth in B-hIL1B mice, demonstrating that the B-hIL1B mice provide a powerful preclinical model for in vivo evaluation of anti-human IL1B antibodies. Values are expressed as mean ± SEM


In vivo efficacy of anti human IL1B antibody

from clipboard



Antitumor activity of anti-human IL1B antibodies in B-hIL1B mice. (A) Anti-human IL1B antibody inhibited MC38 tumor growth in B-hIL1B mice. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hIL1B mice (female, n=6). Mice were grouped on the first day, at which time they were treated with anti-human IL1B antibody. (B) Body weight changes during treatment. As shown in panel A, anti-human IL1B antibody was efficacious in controlling tumor growth in B-hIL1B mice, demonstrating that the B-hIL1B mice provide a powerful preclinical model for in vivo evaluation of anti-human IL1B antibodies. Values are expressed as mean ± SEM